IND Swift Laboratories Ltd

Ind-Swift Laboratories has a strong capital structure, with a debt-to-equity ratio of 0.03, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 3.92, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's operating cash flow is negative at -254.7 million INR, which may raise concerns about its ability to generate cash from operations. In terms of profitability, Ind-Swift Laboratories demonstrates a return on equity of 21.35% and a return on assets of 17.41%, both of which are strong indicators of efficient use of equity and assets. The company's operating income of 1.82 billion INR and net income of 2.5 billion INR further support its profitability. These figures are in line with the industry's preferred metrics, which emphasize high returns on equity and assets. The company's revenue is concentrated in the Pharmaceutical Business segment, with no disclosed geographic diversification. This concentration may pose a risk if the pharmaceutical market experiences a downturn. The company's primary products include APIs and Impurities, with a focus on therapeutic categories such as Macrolide Antibiotic, Cardiovascular, and Antidiabetic. The company's product portfolio includes Clarithromycin, Atorvastatin Calcium, and Clopidogrel HCl, among others. Looking at the growth trajectory, the company's revenue has shown a positive trend, with a revenue of 5.62 billion INR in the latest period. The outlook for the current fiscal year is positive, with expected growth in revenue and profitability. The company's capital expenditure of -644.06 million INR indicates a reduction in capital spending, which may be a strategic move to preserve cash. The risk assessment for Ind-Swift Laboratories highlights a medium liquidity risk and a low dilution risk. The company's key financial flags include a negative net cash position after subtracting total debt, which may affect its liquidity. The dilution potential is low, with no significant dilution sources identified in the latest filings. The company's financial structure and profitability suggest a stable position, but the negative operating cash flow is a concern. Recent events and filings indicate that the company has not disclosed any major events that would significantly impact its operations or financial position. The company's financial statements and disclosures are consistent with its historical performance, and there are no indications of material changes in its business model or strategy.